Related Experiment Video
Updated: Apr 13, 2026
09:09
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
2.4K
Genotype-based clinical trials in cardiovascular disease
Naveen L Pereira1, Daniel J Sargent2, Michael E Farkouh3
1Division of Cardiovascular Diseases, Department of Internal Medicine, 200 First Street SW, Rochester, MN 55905, USA.
Nature Reviews. Cardiology
|May 6, 2015
Summary
Pharmacogenomics aims to personalize medicine by matching drugs to patients, but clinical use is hindered by a lack of genotype-based randomized clinical trials (RCTs). Overcoming ethical and practical hurdles is key for implementing these trials.
Area of Science:
- Pharmacogenomics and personalized medicine
- Clinical trial design
- Genetics and drug response
Background:
- Randomized clinical trials (RCTs) typically assess average treatment effects in homogeneous populations.
- Interindividual variability in drug response and adverse effects is well-documented.
- Pharmacogenomics offers potential for tailored therapies but faces implementation challenges.
Purpose of the Study:
- To explore the need for and challenges of genotype-based RCTs in pharmacogenomics.
- To highlight the potential benefits of personalized medicine through pharmacogenetics.
- To discuss ethical, legal, and practical considerations for genotype-based clinical trials.
Main Methods:
- Review of existing literature on RCTs, pharmacogenomics, and clinical implementation.
- Discussion of technological, statistical, and modeling advances in pharmacogenomics.
- Analysis of ethical, legal, and practical issues related to genotype-based RCTs.
Main Results:
- RCTs provide average treatment effects, not accounting for individual variability in drug response.
- Pharmacogenomics has advanced significantly, but clinical application is limited by a lack of benefit-demonstrating RCTs.
- Genotype-based RCTs could individualize therapy, maximize efficacy, minimize adverse effects, and potentially reduce trial costs.
Conclusions:
- Genotype-based RCTs are crucial for the clinical implementation of pharmacogenetic principles.
- Addressing ethical, legal, and practical challenges is essential for conducting these trials.
- The role of pre-emptive genotyping in electronic health records versus dedicated RCTs requires further investigation.
Related Concept Videos
01:11Clinical Trials: Overview
5.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.5K
01:29Pharmacogenomics: Identification of New Drug Targets
92
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
92
01:16Clinical Trials
11.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
11.2K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
126
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
126
01:27Principles of Pharmacogenetics: Types of Genetic Variants
113
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
113
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
4.6K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.6K